02563nam 2200673 a 450 991082262920332120240313143147.09783527651085352765108X978129924120612992412049783527651115352765111X97835276511083527651101(CKB)2670000000337445(EBL)1123660(SSID)ssj0000990601(PQKBManifestationID)11544702(PQKBTitleCode)TC0000990601(PQKBWorkID)10987429(PQKB)10284427(Au-PeEL)EBL1123660(CaPaEBR)ebr10662582(CaONFJC)MIL455370(OCoLC)826637765(MiAaPQ)EBC1123660(PPN)178875457(Perlego)999796(EXLCZ)99267000000033744520130306d2013 uy 0engur|n|---|||||txtccrAnalogue-based drug discovery III /edited by János Fischer, C. Robin Ganellin and David P. Rotella1st ed.Weinheim, Germany Wiley-VCH20131 online resource (405 p.)Description based upon print version of record.9783527330737 3527330739 Includes bibliographical references and index.pt. 1. General aspects -- pt. 2. Drug classes -- pt. 3. Case studies.Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtuDrug developmentDrug development.615.19Fischer János881301Ganellin C. R(C. Robin)881302Rotella David P1661495MiAaPQMiAaPQMiAaPQBOOK9910822629203321Analogue-based drug discovery III4017436UNINA